Back to Search Start Over

Analysis of risk factors for neurological symptoms in patients with purely hepatic Wilson's disease at diagnosis.

Authors :
Diao, Sheng-Peng
Zhuang, Yang-Sha
Huang, Ye-Qing
Zhou, Zhi-Hua
Liu, Ai-Qun
Hong, Ming-Fan
Source :
BMC Neurology. 2/28/2023, Vol. 23 Issue 1, p1-7. 7p.
Publication Year :
2023

Abstract

Objective: To analyze and explore the risk factors for neurological symptoms in patients with purely hepatic Wilson's disease (WD) at diagnosis. Methods: This retrospective study was conducted at the First Affiliated Hospital of the Guangdong Pharmaceutical University on 68 patients with purely hepatic WD aged 20.6 ± 7.2 years. The physical examinations, laboratory tests, color Doppler ultrasound of the liver and spleen, and magnetic resonance imaging (MRI) of the brain were performed. Results: The elevated alanine transaminase (ALT) and aspartate transaminase (AST) levels and 24-h urinary copper level were higher in the purely hepatic WD who developed neurological symptoms (NH-WD) group than those in the purely hepatic WD (H-WD) group. Adherence to low-copper diet, and daily oral doses of penicillamine (PCA) and zinc gluconate (ZG) were lower in the NH-WD group than those in the H-WD group. Logistic regression analysis showed that insufficient doses of PCA and ZG were associated with the development of neurological symptoms in patients with purely hepatic WD at diagnosis. Conclusion: The development of neurological symptoms in patients with purely hepatic WD was closely associated with insufficient doses of PCA and ZG, and the inferior efficacy of copper-chelating agents. During the course of anti-copper treatment, the patient's medical status and the efficacy of copper excretion should be closely monitored. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14712377
Volume :
23
Issue :
1
Database :
Academic Search Index
Journal :
BMC Neurology
Publication Type :
Academic Journal
Accession number :
162138513
Full Text :
https://doi.org/10.1186/s12883-023-03105-w